Introduction
Neurodegenerative disorders charac terized by accumulation of amyloidogenic proteins, such as Alzheimer disease (AD) and Parkinson dis ease (PD), are major causes of morbidity in the aging population. Development of novel therapies will require an understanding not only of why proteins accumulate locally, but also of how this pathology spreads through out the brain. In fact, progressive accumula tion of protein aggregates across specific brain regions is now recognized as a critical charac teristic in many major neuro degenerative dis orders. 1 In AD, for example, amyloidβ (Aβ) and tau accumulate in extracellular and intraneuronal compartments, whereas PD is characterized by accumulation of the synaptic protein αsynuclein in axons and neuronal cell bodies. In Huntington disease and other triplet expansion diseases, poly glutamine (polyQ) proteins accumulate in both the nucleus and the cytoplasm, and in Creutzfeldt-Jakob disease (CJD) mis folded prions accumulate in the neuropil. Some of these proteins are common to more than one disease. For example, tau aggregates are also found in frontotemporal dementia, progres sive supranuclear palsy and other disorders that are now collectively termed tauo pathies. Mixed Aβ and αsynuclein aggregates are also found in many diseases, including AD, dementia with Lewy bodies, and multiple system atrophy.
In many of the above disorders, neuro degeneration is likely to initiate at the synap tic site, where discrete protein aggregates-known as oligomers-impair neuronal trans mission and functioning. Oligo mers are usually the diffusible, non fibrillar, smallorder aggre gates, whereas larger polymers, in the form of amyloid fibrils, comprise the inclusion bodies and extra cellular deposits that charac terize these disorders and are now believed to represent a pathway for sequestration of moretoxic oligomers. 2 Different types of Aβ oligo mers are associated with varying degrees of toxicity. 3 These oligo mers are thought to differ in their underlying structure, and may follow different assembly pathways, some of which eventually lead to fibril forma tion. 3 Intermediates along the pathway from oligo mer to fibril have also been reported to form 'porelike' structures that might them selves disrupt cellular ionic homeostasis and contribute to cell death. 4 The mechanisms through which oligo mers are generated and neurodegeneration is triggered are under extensive investi ga tion, and alterations in the balance of protein synthesis, folding and clearance (due either to familial mutations or post translational modifications) have all been postu lated to have important roles (Figure 1) . Evidence from prion studies suggests that protein propaga tion might contribute not only to the spread ing and progression of the disease, but also to neuro degeneration ( Figure 1) . 5 Recent studies suggest that such protein spread ing might also be at play in AD, PD, fronto temporal dementia, Huntington disease and other neuro degenerative disorders.
Contrasting views exist regarding the initia tion of protein aggregation in neuro degenera tive diseases. One hypothesis considers that formation of inclusion bodies is a multi focal event, with lesions in each brain region being independent of others. Alternatively, the patho logy could initiate in a few discrete regions and then disseminate to other areas via a prionlike mechanism of propagation with spreading of protein aggregation. Stag ing of pathological severity for AD 6 and Lewy body disease 7 suggests a predict able spread ing pattern. In AD, tau aggregates first appear in the trans entorhinal cortex and spread through the hippocampal forma tion into broad areas of neocortex, whereas in PD αsynuclein aggregation in the CNS initiates in the lower brainstem nuclei and sequentially propagates into the midbrain, mesocortical and neocortical regions.
The main aim of this article is to discuss a conceptual and mechanistic perspective that is emerging from new evidence suggesting a role for prionlike spreading of protein aggregates in nonprion neuro degenerative disorders (see Box 1 for an explanation of terminology).
Prion-like spreading
The concept of propagation of disease by 'infectious' protein particles in the CNS has been confined to prions for two decades. Out side the CNS, prionlike behavior has been described for systemic A amyloido sis and apolipoprotein AII (ApoAII) amyloidosis. 8, 9 Emerging evidence from many neuro degenerative diseases has now expanded the notion of spreading of protein aggregates to include several nonprion Protein misfolding and templated assembly into aggregates might result from an imbalance between protein synthesis, aggregation and clearance. Although protein misfolding and aggregation occur in most neurodegenerative disorders, the concept of spreading and infectivity of aggregates in the CNS has, until now, been confined to prion diseases such as CJD and bovine spongiform encephalopathy. Emerging evidence, however, suggests that prion-like spreading, involving secreted proteins such as amyloid-β and cytosolic proteins such as tau, huntingtin and α-synuclein, can occur in other neurodegenerative disorders. The underlying molecular mechanisms and the therapeutic implications of the new data are discussed in this article.
structures (Table 1) . Evidence of propaga tion of Aβ, tau, αsynuclein and polyQ pro teins has been extensively reported, although the mechanisms governing the spreading of these nonprion aggregates remains to be elucidated.
Molecular mechanisms
Seeded aggregation Despite the seemingly unrelated primary structures of monomer subunits, disease linked protein aggregates have common conformational properties, 10 which provide a compelling argument for the existence of a general pathogenic principle that underlies different neurodegenerative disorders. In support of this hypothesis, protein aggre gation processes in neurodegenerative diseases feature similar kinetics, whereby aggregate growth is preceded by a long lag phase during which nuclei are formed. The addition of preformed aggregates eliminates the lag phase 11 -a process known as 'seeded' polymerization, which, in combination with aggregate breakage, represents the theoretical basis for prion transmission, or 'infecti vity' . This effect, which has been widely investi gated for polymers that form fibrils, might also exist for oligomers.
During the course of seeded poly meriza tion, subtle conformational variations in aggregates are propagated through structural conversion of newly added monomers. This conformational propagation, which is charac teristic of prion strains, has recently been reported for other diseaselinked proteins, such as Aβ, 12 αsynuclein 13 and tau, 14 raising the possibility that neuro degenerative patho logies involving protein aggregation could spread within the brain via a mechanism analogous to prionlike selfpropagation.
A critical issue in this hypothesis is whether the transferred cytoplasmic aggregates are indeed amplified via seeded poly merization of the endogenous protein. Such mechanisms have been reported for both tau and polyQ aggregates: addition of exogenous aggregates to cell cultures induced the aggregation of endogenous, otherwise soluble cytoplasmic proteins. 15, 16 Internalized aggregates induced the aggregation of endogenous proteins 16 of their own kind, suggesting that this process is driven by a sequencespecific interaction between the exogenous nuclei and the endo genous monomers. For example, cationic liposomemediated delivery of αsynuclein fibrils into cultured cells induced the forma tion of Lewylike inclusions, 17 whereas hippo campal injections of brain extracts from transgenic mice with distinct plaque
Box 1 | Definitions
Several recent studies have reported the propagation of non-prion protein aggregates in many neurodegenerative diseases. While the idea of considering traditional neurodegenerative diseases as prion diseases is under debate, a clear definition of terminology will shed light on setting common features and particularities of the propagation mechanisms of both types of protein entities. For that purpose, we propose in this article to reserve the term 'infectivity' to refer specifically to the conveyance of prion proteins from animal to animal, while the term 'transmission' would be extended to include the conveyance of non-prion proteins. The terms 'propagation', 'spreading' and 'dissemination', on the other hand, might be used interchangeably to refer to the dispersal of the protein over a larger area and from cell to cell.
patterns produced Aβ deposition in the host. 18 This prion strainlike phenomenon is a strong indication of the seedingdependent selfpropagation of aggregates.
In addition, crossseeding between dis similar proteins that share β sheet struc ture has been described. The best evidence for this type of propagation comes from nonCNS amyloidoses (such as amyloid A or ApoAII amyloidosis), 9 but crossseeding of Aβ and αsynuclein, 4 tau and αsynuclein, 19 and prion protein and Aβ 20 has been demon strated. Alternative mechanisms, such as the disruption of basic cellular proteostasis by ex ogenous aggregates, cannot be excluded. 21 Reaching neighboring cell cytosol Unlike Aβ and prions, which are naturally exposed to the extracellular space, cyto solic proteins such as tau, αsynuclein, polyQ and other diseaselinked proteins must cross membrane barriers at least twice before they gain access to the neighboring cell's cytosol. Mechanisms must, therefore, exist whereby these proteins are released from neurons and subsequently enter another neuron's cytosol. These mechanisms could include exocytosis, cell injury, exosomes, and/or tunneling nano tubes ( Figure 2 ). The αsynuclein protein and its aggregated forms are secreted at low levels in neuronal cultures, although this secretion is increased under protein misfolding stress, suggesting the existence of release mecha nisms that are susceptible to dys regulation under disease conditions. 22 Consistent with this notion, in PD and AD patients αsynuclein and tau, respectively, are present in blood and CSF in both monomeric and oligo meric forms, 23, 24 suggesting that release of normally intra cellular proteins might be a common event in neurodegenerative dis orders. In addition to secretory mechanisms, neuronal protein aggregates might be released from severely injured neurons through membrane disruption or pore formation. 4 Once released, protein aggregates, such as αsynuclein and tau, 15, 25 are inter nalized through endocytosis and packaged into endocytic vesicles; therefore, another mecha nism is required for these aggregates to gain access to the host cytosol (Figure 2) . Notably, protein aggregates can disrupt lipid bilayers such as endocytic vesicle membranes-a mechanism that grants them access to the cytosolic space. Endocytosis and subsequent delivery to late endosomes may concentrate the inter nalized proteins, forming aggregates that might seed endogenous protein aggre gation. 26 Direct membrane penetration is another plausible mechanism of entry, since internalized polyQ aggregates do not seem to be enclosed within vesicles. 16 In the case of prions, intercellular trans mission by means of exosomes 27 or tunnel ing nanotubes 28 has been suggested, and similar mechanisms could be at work in the transmission of other aggregated proteins (Figure 2 ).
Spreading via neural connections
Considering that αsynuclein, as well as other proteins involved in neurodegeneration, is enriched at synaptic sites, aggregates trans ferred from postsynaptic cells would have an ample supply of native proteins to convert in the presynaptic terminal (Figure 2 ). Cellular prions are transported via both fast antero grade and retrograde axonal transport, and internalization and movement of the scrapie form of prion along neuronal processes has also been re ported. 29 The routes of aggre gate transmission are probably determined by the unique cell biological characteristics of particular proteins, including the loca tion of protein aggregation in the neuron, the mechanism of intraneuronal transport, and the manner in which the aggregates are released. In addition, synaptic activity might influence the release and transmission of cytosolic proteins, since synaptic stimulation has been shown to induce secretion of Aβ, 30 promote amyloid precursor protein (APP) transport, and regulate synaptic localiza tion of αsynuclein, 31 although the precise mechanism s remain to be addressed.
Molecular species responsible
Important issues to address are which mol ecular species are responsible for aggregate Figure 2 | Models of cell-to-cell transmission of misfolded and aggregated proteins. Proteins might be released from neurons via vesicle-mediated exocytosis (1) or leakage through damaged membranes (2) and be internalized into neighboring neurons via endocytosis or direct membrane penetration. Alternatively, proteins could be transmitted to neighboring neurons by packaging into exosomes (3) or through tunneling nanotubes (4) . Different mechanisms might work simultaneously, with specific proteins preferring certain pathways. Mechanisms might act between the cell bodies or trans-synaptically (5). Internalized aggregates (pink) might act as seeds for aggregation of endogenous native proteins (green). Seeded aggregation may produce toxic aggregate species, leading to formation of pathological inclusion bodies.
propagation, and whether these species are responsible for neurotoxicity. If the neuro toxic species are generated during the course of the seedingdependent aggregate propaga tion process, are they generated as the final product or as relatively stable intermediates? Whether a common structural motif exists in these molecular species, regardless of the con stituent subunits, is another important ques tion. These considera tions are highly rele vant to diagnosis and drug development.
A related issue is whether or not the aggre gate propagation mechanism involves co factors that cooperate with the aggregate itself. Consistent with the involvement of cofactors, pure protein aggregates of prion or Aβ injected into mouse brains showed either no transmission or very low trans mission rates, 18, 32 whereas efficient trans mission processes were observed on injection of ag gregatecontaining tissue extracts. The cellular form of prion protein seems to have various functions and to interact with a wide range of molecules (reviewed elsewhere 33 ), suggesting that pathogenic conversion of the free protein may not occur in vivo. Although the aggregateinducing abilities of pure protein aggregates of tau and polyQ proteins have been shown in tissue culture systems, they remain to be validated in animal models.
Propagation properties
Protein aggregation and spreading seem to be common features of several neuro degenera tive disorders, but whether these disorders qualify as 'infectious' diseases analogous to prion diseases remains unclear. In APP trans genic mice, βamyloidosis was not induced by oral, intravenous, intraocular or intra nasal Aβ inocula tions; however, direct contact of the host brain with Aβcontaminated wires triggered βamyloidosis. 34 Differences in trans mission might be attributed to the pres ence or absence of a system that transports seeding particles from the periphery to the CNS. Whether peripheral and systemic trans mission of αsynuclein, tau and polyQ protein s occurs is not yet known.
Propagation of prion aggregates can occur at a relatively fast and efficient pace. This propagation is accelerated when the aggre gate breaks into smaller seeds that serve to recruit additional monomers (Figure 1) . Prion aggregate stability correlates with the incuba tion period to terminal disease, suggesting that a more fragile aggregate might break rapidly and produce seeds, thereby accelerating propagation. 29 Prions may, therefore, be more easily fragmented in vivo to produce small seeds than are other protein aggregates. The stability of amyloid fibrils can vary dramatic ally, but the effects of this variation on propagation remain to be determined.
The specific localization of soluble mono mers or seeds could have a role in the speed of protein recruitment. The prion protein is anchored to glycophosphatidylinositol in lipid rafts at the plasma membrane, 33 and this high local concentration of protein might lead to moreefficient conversion and spread at the cell surface than in the case of cytoplasmic aggregates.
Cellular clearance mechanisms counter balance aggregate amplification (Figure 1 ). The ease of protein clearance may vary with the aggregate conformation, size, stability and abundance; with the intra cellular or extracellular trafficking patterns; and with the cell type that is producing the aggregates. Any deficit in cellular clearance mecha nisms would amplify aggregate formation by increasing the likelihood of interactions between the seed and the un aggregated form of the protein.
Effects of aggregate spreading
Studies have shown that experimental aggre gate propagation of tau 35 or Aβ plaques 18 in mouse models is often not accompanied by neuronal loss. Three possible scenarios might explain this observation. First, aggre gate deposition could simply precede neu ronal loss and other pathological changes. Second, aggregate propagation may be a cri tical factor-but not in itself sufficient-for neuro degeneration; in this case transmitted aggregates could cooperate with unknown factors that are in limited supply in the mouse models. Third, the progression of protein aggregation and neuro degeneration could be entirely unrelated and independent events.
Interestingly, different physiological res ponses related to the nature of the host brain are observed. Grafting of mouse neu ronal pro genitor cells into the brains of αsynuclein trans genic mice showed that αsynuclein uptake was accompanied by increased caspase3 activation. 36 In human studies, grafted dopamine neurons showed a reduction in dopamine transporter and tyrosine hydroxy lase activity (as well as Lewy bodylike inclusions), indicating functional decline in the long term, yet no evidence for neuronal loss was found in the transplanted tissues. [37] [38] [39] These results support the notion that the propagation of protein aggregates is linked to neurotoxicity. In human PD cases, spreading of Lewy bodies does not always seem to be associated with neuronal dys function and degeneration. One approach to determine whether aggregate propaga tion is a direct cause of neurodegeneration would be to identify the molecular species of proteins that are responsible for aggre gate spreading and to assess their abilities to induce pathology. Elucidation of the role of aggregate spreading in neurodegeneration not only increases our understanding of the basic mecha nisms of disease progression, but also provides the crucial information needed to enhance our current approach to cell replacement therapy.
Therapeutic implications
Potential therapeutic opportunities to target aggregate transmission should be explored. Passive and active immunization has already been proposed as a promising new direc tion in light of studies showing success ful reduction in protein aggregate loads in transgenic mouse models of AD (Aβ and tau), synucleinopathies and prion diseases. 40 Some approaches seemingly have safety and clinical effectiveness issues, but immu nization targeting the transmitting aggre gate proteins may, nevertheless, be a viable treat ment approach. The identification of speci fic molecular species that are capable of spreading the aggregates will allow refine ment of the immunization approach towards pathogenspecific therapy.
Another beneficial avenue could involve enhancing the endolysosomal pathway in general and antagonizing the specific recep tor for protein internalization, although this approach carries the risk of undesirable side effects. If direct transmission were indeed the crucial mechanism of disease progression, the most attractive and speci fic therapeutic approach would be to target the extra cellular pathogenic protein aggregates . Specific binding agents to the ag gre gates might pre vent uptake and seeding in neurons. These agents could be chemical compounds, pep tides or ribonucleic acids, and might func tion as blocking agents-thereby preventing disease progression and neurodegenerationor perhaps as tracers for pre symptomatic diag nosis. Again, identi fication of the mol ecular species responsible for transmission of aggre gates and neuro toxicity will aid the refinement of drug targets. If one can target a common conformational element that many patho genic molecular species share, development of drugs to treat multiple neurodegenerati ve diseases might be possible.
Enhancement of gliamediated clearance of extracellular aggregates could be another therapeutic approach. Extracellular aggre gates of Aβ and αsynuclein have been shown to activate and be cleared by both astrocytes and microglia, 41 with lysosomes being res ponsible for the degradation of internalized proteins in both neuronal and glial cells. 25 Several studies have shown that autophagy plays an important part in the degradation of aggregated proteins in the cyto plasm, 42 so investigating whether this mechanism is involved in the clearance of transmitted protein aggregates would be informative. Aging and agerelated dis orders are gen erally associated with functional decline of lysosomes, 43 and genetic depletion of lysosomal hydrolases causes many human neuro degenerative diseases. Stimulation of lysosomal degradation acti vity may, therefore, be another promising approach to therapy.
Conclusions
Prionlike spreading of aggregates could be a general principle that underlies pro gressive neurodegeneration associated with protein misfolding, and has profound implications for cellreplacement thera pies. Understanding the mechanisms of patho logical spreading is crucial if we are to develop diagnostic techniques and novel therapies for protein misfoldingassociated neuro degenerative diseases.
